Latest Administration News

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Discovery Alaska Limited has detailed its exploration expenditures and strategic pivot from Alaskan projects to new US acquisitions, affirming its financial health and operational sufficiency to maintain its ASX listing.

Fiducian Group Limited has reported a robust 23% increase in net profit after tax for the year ended June 2025, driven by strong inflows and resilient performance across its financial planning, platform administration, and investment management segments despite challenging market conditions.

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

Netwealth Group Limited has reported a landmark quarter with total Funds Under Administration soaring to $120.8 billion, driven by record first-quarter net flows of $4.1 billion and strategic service expansions.

Queste Communications reports steady investment holdings and a robust cash reserve of over $4 million for the quarter ending September 2025, underpinned by its controlling stake in Orion Equities.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

IODM Limited reports a striking 179% revenue surge in its UK Education segment for September 2025, driving a 210% year-to-date increase and prompting an upward revision of first-quarter group cash receipts.